The FDA has eliminated Risk Evaluation and Mitigation Strategies (REMS) for six approved CAR T cell therapies targeting BCMA and CD19 in multiple myeloma and certain leukemias and lymphomas. This regulatory shift is based on accumulated real-world evidence and established treatment guidelines addressing cytokine release syndrome and immune effector cell-associated neurotoxicity. Cell and gene therapy leaders, including FDA officials, welcomed the change as it reduces provider burden and accelerates therapy availability in community healthcare settings. Reduced patient post-treatment restrictions on driving and proximity to healthcare facilities further ease patient management, potentially broadening the reach of CAR T therapies.